

1 **Clinical characteristics and factors associated with admission to intensive care units in**
2 **hospitalized COVID-19 patients in Lyon University Hospitals, France**

3 **Short title: Characteristics of COVID-19 patients at admission in Lyon University Hospitals**
4 **and factors of severity**

5 Philippe Vanhems^{1, 2}, Marie-Paule Gustin^{1, 2}, Christelle Elias^{1, 2}, Laetitia Henaff^{1, 2}, Cédric
6 Dananché^{1, 2}, Beatrice Grisi^{1, 2}, Elodie Marion¹, Nagham Khanafer^{1, 2}, Delphine Hilliquin^{1, 2},
7 Sophie Gardes¹, Solweig Gerbier-Colomban¹, Selilah Amour^{1, 2}, Elisabetta Kuczewski¹,
8 Vanessa Escuret^{3, 4}, Bruno Lina^{3, 4}, Mitra Saadatian-Elahi^{1, 2}

9 On behalf of COVID-Outcomes-HCL Consortium

10 Laurent Argaud, Frédéric Aubrun, Marc Bonnefoy, Maude Bouscambert-Duchamp, Roland
11 Chapurlat, Dominique Chassard, Christian Chidiac, Michel Chuzeville, Cyrille Confavreux,
12 Sébastien Couraud, Gilles Devouassoux, Isabelle Durieu, Michel Fessy, Sylvain Gaujard,
13 Alexandre Gaymard, Arnaud Hot, Géraldine Martin Gaujard, Emmanuel Morelon, Vincent
14 Piriou, Véronique Potinet, Jean-Christophe Richard, Thomas Rimmele, Pascal Sève, Alain
15 Sigal, Karim Tazarourte.

16 ¹ Service Hygiène, Epidémiologie, Infection, Vigilance et Prévention, Centre Hospitalier
17 Edouard Herriot, Hospices Civils de Lyon, Lyon, France

18 ² CIRI, Centre International de Recherche en Infectiologie, (Equipe Laboratoire des
19 Pathogènes Emergents), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS,
20 UMR5308, ENS de Lyon, F-69007, Lyon, France.

21 ³ Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de la Croix-Rousse,
22 Hospices Civils de Lyon, Lyon, France

23 ⁴ Virpath - Grippe, de l'émergence au contrôle, Centre International de Recherche en
24 Infectiologie (CIRI), Inserm U111, CNRS 5308, ENS, UCBL1, Faculté de Médecine RTH
25 Laënnec, Lyon, France

26 **Correspondence to**

27 Professor Philippe Vanhems

28 Groupement Hospitalier Centre, Unité d'Hygiène, Epidémiologie, Prévention - Bâtiment 1

29 5, place d'Arsonval-69437 Lyon cedex 3

30 Phone: +33 4 72 11 07 20

31 Fax: +33 4 72 11 07 26

32 E-mail: Philippe.vanhems@chu-lyon.fr

33 **Author contribution**

34 PV designed the study. MPG, CE, LH, CD and MSE participated in the design of the CRF. LH,
35 BG, SG, SGC, SA and EK completed the data entry. VE and BL participated in the laboratory
36 analysis. PV, MPG and CE performed the statistical analyses. PV, MPG, CE, CD, EM, NK, DH
37 and MSE reviewed and interpreted the statistical analyses. PV, MPG, CE and MSE drafted the
38 manuscript. All co-authors reviewed and approved the final version of the manuscript.

39 **Abstract**

40 **Introduction:** A new respiratory virus, SARS-CoV-2, has emerged and spread worldwide since
41 late 2019. This study aims at analyzing clinical presentation on admission and the
42 determinants associated with direct admission or transfer to intensive care units (ICUs) in
43 hospitalized COVID-19 patients.

44 **Patients and Methods:** In this prospective hospital-based study, socio-demographic, clinical
45 and biological characteristics, on admission, of adult COVID-19 hospitalized patients were
46 prospectively collected and analyzed. The outcome was admission/transfer to intensive care
47 units compared with total hospital stay in medical wards according to patient characteristics.

48 **Results:** Of the 412 patients included, 325 were discharged and 87 died in hospital.
49 Multivariable regression showed increasing odds of admission/transfer to ICUs with male
50 gender (OR, 1.99 [95%CI, 1.07-3.73]), temperature (OR, 1.37 [95% CI, 1.01-1.88] per degree
51 Celsius increase), abnormal lung auscultation on admission (OR, 2.62 [95% CI, 1.40-4.90]),
52 elevated level of CRP (OR, 6.96 [95% CI, 1.45-33.35 for CRP>100mg/L vs CRP<10mg/L).
53 Increased time was observed between symptom onset and hospital admission (OR, 4.82
54 [95% CI, 1.61-14.43] for time >10 days vs time <3 days) and monocytopenia (OR, 2.49 [95%
55 CI, 1.29-4.82]). Monocytosis was associated with lower risk of admission/transfer to ICUs
56 (OR, 0.25 [95% CI, 0.05-1.13]).

57 **Conclusions:** Clinical and biological features on admission and time until admission were
58 associated with admission to ICUs. Signs to predict worsening on admission could be
59 partially associated with the time until admission. This finding reinforces the need for
60 appropriate guidelines to manage COVID-19 patients in this time window.

61 **Key words**

62 SARS-CoV-2; COVID-19; Hospital-based; Prospective; Lyon; France

63 Introduction

64 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first detected in December
65 2019 in the Hubei province of China [1-3], was declared as a pandemic by the World Health
66 Organization on March 11, 2020. Coronavirus disease 2019 (COVID-19) is the emerging
67 infectious disease due to SARS-CoV-2, mainly associated with lower respiratory infection
68 even though less typical clinical features or asymptomatic cases have also been reported [4,
69 5]. The crude case fatality rate ranges from 2% to 4% but can reach 12% to 15% in the elderly
70 [6].

71 The first cases of SARS-CoV2 infection in Europe were travellers from Wuhan who were
72 tested positive in France (two in Paris and one in Bordeaux) on January 24, 2020 [7]. As of
73 May 3, 2020, 131,287 confirmed cases have been reported in France, including 3,918
74 patients still hospitalized in intensive care units (ICUs) and 15,583 deaths in hospitals [8]. The
75 Auvergne-Rhône-Alpes region located in the southeast of France has a population of more
76 than 6 million inhabitants. The first confirmed case of SARS-CoV-2 in this region was
77 identified on February 8th and had reached 8,431 cases and 1,192 deaths by April 24th.

78 COVID-19 related complications, patient outcomes and mortality rates reported so far
79 have varied considerably between countries most probably owing to differences in
80 healthcare systems and the availability of ICU beds. Moreover, the prevalence of underlying
81 chronic diseases such as obesity and diabetes, known to be important determinants in the
82 clinical course and outcome of COVID-19 [9] are also different throughout the world. In
83 addition, a large number of published reports so far have described hospitalized COVID-19
84 patients with incomplete data vis-à-vis hospital follow-up because a substantial proportion
85 of patients remained hospitalized at the time of manuscript submission or publication.

86 Knowledge of the baseline characteristics and outcomes of hospitalized COVID-19
87 patients from different parts of the world is crucial for the decision-making process at
88 national and international levels in order to properly respond to the pandemic.

89 The aim of this study was to report the clinical features and outcomes of confirmed
90 COVID-19 patients admitted to Lyon university-affiliated hospitals with complete
91 documentation of the hospital stay from February 8 to April 24, 2020 and to identify the
92 demographic, clinical and biological characteristics on admission associated with the risk of
93 direct admission or subsequent transfer to ICUs.

94 **Methods**

95 **Study design and participants**

96 This prospective, observational, hospital-based study (NOSO-COR, ClinicalTrials:
97 NCT04290780) is an ongoing international multicenter study carried out in France and
98 hospitals affiliated with the GABRIEL network [10]. However, the present paper was limited
99 to community-acquired COVID-19 confirmed patients admitted to the four university-
100 affiliated hospitals in Lyon (Hospices Civils de Lyon, 5,300 beds).

101 Any adult patient who presented an infectious syndrome based on the WHO definition
102 of COVID-19 [11], admitted to one of the four participating university-affiliated hospitals in
103 Lyon between February 8 and April 24, 2020, and hospitalized for a period of at least 24
104 hours, was included.

105 The study was approved by the clinical research and ethics committee of Ile de France V
106 on March 8, 2020 (No. 20.02.27.69817 Cat 3).

107 **Data collection**

108 Identification of community-acquired confirmed SARS-CoV-2 patients was based on a daily
109 extraction of real-time reverse transcriptase-polymerase chain reaction (RT-PCR) positive

110 patients from the virology laboratory. Electronic medical records were the main source of
111 data collection. Demographic characteristics, underlying comorbidities, clinical, and
112 biological parameters and patient outcome data were collected prospectively on an
113 electronic case-report form designed especially for the purpose of the project. Clinical
114 outcomes were monitored up to hospital discharge or death. All data were double-checked
115 after computerization.

116 Nasopharyngeal swab samples were collected as part of the standard care in patients
117 presenting signs and symptoms of SARS-CoV-2 infection. Samples were transferred to the
118 French national reference center of respiratory viruses for the detection of SARS-CoV2 by
119 RT-PCR [12]. Patients with positive RT-PCR results were defined as laboratory-confirmed
120 SARS-CoV-2.

121 **Statistical analysis**

122 Given the descriptive nature of this observational study and the emergency context, no
123 statistical sample size calculation was performed. Sample size was equal to the number of
124 patients included during the study period.

125 Continuous variables were reported as median and interquartile range (IQR).
126 Categorical variables were described as frequencies (%). Comparisons between groups were
127 performed using Mann-Whitney or Kruskal-Wallis test and Chi-square or Fisher exact test
128 when appropriate.

129 Univariate logistic regression was first used to identify patient determinants known on
130 admission that were associated with the outcome i.e. admission or transfer to an ICU versus
131 total hospital stay in a medical ward. The determinants that were significant at 0.15 levels in
132 univariate analysis were retained for multivariate analysis. Gender, temperature and the
133 time between the onset of symptoms and hospital admission were first introduced in the

134 multivariable model and then added sequentially to the model. The logistic regression model
135 was applied to 374 patients for whom complete biological data (white blood cells,
136 neutrophil, lymphocyte, monocyte, creatinine, red blood cells, hemoglobin and C-reactive
137 protein) were available. Statistical tests were 2-tailed with a level of statistical significance of
138 $<.05$. Statistical analysis was performed using R language version 3.5.2 ([https://cran.r-](https://cran.r-project.org/)
139 [project.org/](https://cran.r-project.org/)).

140 **Results**

141 **Patient characteristics on admission**

142 From February 8 to April 24, 2020, a total of 412 SARS-CoV-2 confirmed patients with known
143 date of hospital discharge or death were included. Overall, 66 patients (16.0%) were
144 admitted directly to ICUs and 320 (77.7%) were hospitalized in medical wards, of whom
145 26/320 (8.1%) required subsequent transfer to ICUs. Demographic data, clinical signs and
146 symptoms on admission for the overall study population and according to hospitalization
147 ward are summarized in Table 1. Median age was 72.0 years [IQR, 57-83] and 56.3% were
148 men. A total of 188 (45.6%) patients were younger than 70 years, 139 (33.7%) were aged
149 between 70 and 84 years old and 82 (20.6%) were older than 85 years. One or more pre-
150 existing comorbidities were present in 286 patients (69.4%): cardiovascular diseases (47.6%),
151 diabetes (19.9%) and chronic lung diseases (15.0%) being the most common. The most
152 frequently reported signs and symptoms on admission were cough (73.5%),
153 dyspnea/tachypnea (64.3%), general weakness (61.4%) and fever ($>37.8^{\circ}\text{C}$, 57.0%).
154 Abnormal lung auscultation was observed in 229 patients (55.6%).

155 **Table 1.** Demographic and clinical characteristics on admission of 412 confirmed COVID-19
 156 hospitalized patients at Lyon University Hospitals, France

	No. (%)				P-Value ^a
	All patients n=412	Medical ward n=320 (77.7%)	Transfer to ICU n=26 (6.3%)	ICU n=66 (16.0%)	
Age, median (IQR), y	72(57-83)	73(57-84)	74.5(63.8-80.8)	66(54-76.8)	.02
≥75, y	184(44.7)	151(47.2)	13(50)	20(30.3)	.04
<70, y	188(45.6)	141(44.1)	9(34.6)	38(57.6)	.004
70-84	139(33.7)	102(31.9)	14(53.8)	23(34.8)	
≥85	85(20.6)	77(24.1)	3(11.5)	5(7.6)	
Gender					
Female	180(43.7)	155(48.4)	7(26.9)	18(27.3)	.001
Male	232(56.3)	165(51.6)	19(73.1)	48(72.7)	
Comorbidities					
Cardiovascular disease ^a	196(47.6)	161(50.3)	14(53.8)	21(31.8)	.02
Diabetes	82(19.9)	64(20)	6(23.1)	12(18.2)	.85
Chronic lung disease	62(15)	48(15)	8(30.8)	6(9.1)	.04
Renal diseases	56(13.6)	39(12.2)	4(15.4)	13(19.7)	.22
Malignancy	55(13.3)	42(13.1)	4(15.4)	9(13.6)	.89
Chronic neurological diseases	53(12.9)	46(14.4)	4(15.4)	3(4.5)	.06
Liver diseases	27(6.6)	21(6.6)	1(3.8)	5(7.6)	.87
Immunodeficiency	26(6.3)	20(6.2)	2(7.7)	4(6.1)	.93
Symptoms and signs					
Temperature (°C)	38(37-38.5)	38(37-38.4)	38.5(38-39)	38.2(37.2-39)	<.001
Fever (>37.8°C)	235(57)	174(54.4)	20(76.9)	41(62.1)	.05
Fever (>39.0°C)	37(9)	22(6.9)	5(19.2)	10(15.2)	.01
Cough	303(73.5)	237(74.1)	22(84.6)	44(66.7)	.21
General weakness	253(61.4)	199(62.2)	14(53.8)	40(60.6)	.70
Shortness of breath	212(51.5)	141(44.1)	13(50)	58(87.9)	<.001
Diffuse pain	123(29.9)	107(33.4)	4(15.4)	12(18.2)	.01
Diarrhea	113(27.4)	89(27.8)	8(30.8)	16(24.2)	0.77
Myalgia	85(20.6)	71(22.2)	4(15.4)	10(15.2)	.40
Headache	67(16.3)	55(17.2)	5(19.2)	7(10.6)	.37
Nausea	54(13.1)	43(13.4)	6(23.1)	5(7.6)	.14
Runny nose	49(11.9)	40(12.5)	1(3.8)	8(12.1)	.54
Confusion	35(8.5)	27(8.4)	2(7.7)	6(9.1)	.95
Abdominal pain	33(8)	31(9.7)	1(3.8)	1(1.5)	.05
Sore throat	24(5.8)	20(6.2)	1(3.8)	3(4.5)	.92
Chest pain	14(3.4)	12(3.8)	0(0)	2(3)	.89
Joints pain	8(1.9)	7(2.2)	0(0)	1(1.5)	>.99
Dyspnea /tachypnea	265(64.3)	186(58.1)	20(76.9)	59(89.4)	<.001

157 **Table 1:** continue

	No. (%)				
	All patients n=412	Medical ward n=320 (77.7%)	Transfer to ICU n=26 (6.3%)	ICU n=66 (16.0%)	P-Value^a
Abnormal lung auscultation	229(55.6)	163(50.9)	20(76.9)	46(69.7)	.001
Pharyngeal exudate	27(6.6)	21(6.6)	1(3.8)	5(7.6)	.87
Duration of symptoms, median (IQR)[n]^c, d	16(13-21) [232]	15(12-18.8) [198]	21.5(20.2-26.2) [10]	23(20.8-27.8) [24]	<.001
LOS (Alive), median (IQR)[n]^c, d	9(4-13) [326]	8(4-12) [276]	13.5(11-19.2) [14]	12(9-17.2) [36]	<.001
LOS (Deceased) median (IQR)[n]^c, d	10(6-14) [86]	8.5(6-13) [44]	13(9-21.2) [12]	10.5(5-15.5) [30]	.05
Time between onset of symptoms and hospital admission, median (IQR), d	6(3-9)	6(2-9)	5.5(3.2-10)	7(4-11)	.006
< 3	94(22.8)	84(26.2)	5(19.2)	5(7.6)	.001
3-10	65(15.8)	43(13.4)	3(11.5)	19(28.8)	
>10	253(61.4)	193(60.3)	18(69.2)	42(63.6)	

158 COVID-19: coronavirus disease 2019; ICU: Intensive care unit; IQR: interquartile range; LOS: length of stay.

159 ^aP-values indicate differences between at least two groups of patients out of the three groups: patients

160 admitted to medical wards, patients transferred from medical wards to ICUs and patients admitted to ICUs.

161 *P* < .05 was considered statistically significant

162 ^bCardiovascular disease included hypertension and heart failure

163 ^c[n] indicates the patients without missing values for continuous variables

164

165 Males were significantly more prone to hospitalization in ICUs ($P = .001$). The
166 proportion of patients with comorbidities was similarly distributed among medical wards
167 and ICUs except for cardiovascular diseases ($P = .02$) and chronic lung diseases ($P = .04$).
168 Diffuse or abdominal pain were reported significantly more often in patients hospitalized in
169 medical wards ($P = .01$ and $P = .05$ respectively). Patients admitted or transferred to ICUs
170 presented more often with fever ($>37.8^{\circ}\text{C}$, 62.1% and 76.1% vs 54.4%; $P = .05$), shortness of
171 breath (87.8% vs 44.1% and 50%; $P < .001$), showed more frequently abnormal lung
172 auscultation (69.7% and 76.9% vs 50.9%; $P = .002$) and suffered from dyspnea/tachypnea
173 (89.4% and 76.9% vs 58.1%; $P < .001$). In 232 patients, the duration of symptoms ((median,
174 23 [IQR, 20.8-27.8]; $P < .001$) was significantly higher in those admitted to ICUs while the time
175 between symptom onset and hospital admission was significantly lower in patients
176 hospitalized in medical wards (median, 6 [IQR, 2-9] and 5.5[IQR,3.2-10] vs 7[IQR,4-11]; $P =$
177 .006).

178 As of April 24, 2020, 87 (21.1%) patients had died. The crude case fatality rate differed
179 between patients hospitalized in medical wards (14.1%), and those directly admitted to ICUs
180 (45.5%) or transferred to ICUs (46.2%) ($P < .0001$).

181 Initial biological data on admission are represented in Table 2. The majority of biological
182 parameters were in the normal range although their values differed between patients
183 admitted to ICUs and those hospitalized in medical wards. We noted that half of the
184 population had marked lymphopenia, in particular, ICU patients (Median 0.7, [IQR, 0.6-1.1];
185 $P = .0004$). Elevated levels of lactate dehydrogenase (LDH) (N=134, Median 330.5, [IQR,
186 236.5-419.6]) and C-reactive protein (CRP) (N=378, median 60.7, [IQR, 23.4-122.3]) in half of
187 the study population on admission were also noted. Analysis by hospital ward showed that
188 the highest values of these parameters were found in patients directly admitted to ICUs.

189 **Table 2.** Laboratory measures on admission of confirmed Covid-19 hospitalized patients at Lyon University Hospitals, France

	Median (IQR)		All patients n=412	Medical ward n=320 (77.7%)	Transfer to ICU n=26 (6.3%)	ICU n=66 (16.0%)	P-value ^a
	Units	Reference range					
White blood cell count ^b	10 ⁹ /L	[4-10]	6.1(4.6-8.4)[400]	5.9(4.5-7.9) [308]	5.7(4-6.5) [26]	8.1(6.1-10.1) [66]	<.001
< 4, n (%)			62(15.5)	49/320(15.9)	7/26(26.9)	6/66(9.1)	0.01
4-10			284(71)	224/320(72.7)	17/26(65.4)	43/66(65.2)	
> 10			54(13.5)	35/320(11.4)	2/26(7.7)	17/66(25.8)	
Neutrophil count	10 ⁹ /L	[1.8-7.5]	4.4(3-6.4)[400]	4.1(2.8-5.9)[308]	4.4(2.6-5.1)[26]	6.4(4.4-8.4)[66]	<.001
< 1.8, n (%)			33(8.2)	30/320(9.7)	2/26(7.7)	1/66(1.5)	<.001
1.8-7.5			304(76)	242/320(78.6)	23/26(88.5)	39/66(59.1)	
> 7.5			63(15.8)	36/320(11.7)	1/26(3.8)	26/66(39.4)	
Lymphocyte count	10 ⁹ /L	[1-4]	0.9(0.6-1.3)[400]	1(0.7-1.4)[308]	0.7(0.5-0.9)[26]	0.7(0.6-1.1)[66]	<.001
< 1, n (%)			225(56.2)	160/320(51.9)	20/26(76.9)	45/66(68.2)	.002
1-4			169(42.2)	145/320(47.1)	5/26(19.2)	19/66(28.8)	
> 4			6(1.5)	3/320(1)	1/26(3.8)	2/66(3)	
Monocyte count	10 ⁹ /L	[0.2-0.9]	0.5(0.3-0.6)[400]	0.5(0.4-0.7)[308]	0.3(0.2-0.5)[26]	0.4(0.3-0.5)[66]	<.001
< 0.2, n (%)			25(6.2)	12/320(3.9)	5/26(19.2)	8/66(12.1)	.002
0.2-0.9			342(85.5)	266/320(86.4)	20/26(76.9)	56/66(84.8)	
> 0.9			33(8.2)	30/320(9.7)	1/26(3.8)	2/66(3)	
Platelet count	10 ⁹ /L	[150-400]	195(154-258.5)[395]	195(155-257)[305]	165(142-212)[25]	209(157-312)[65]	.02
< 150, n (%)			91(23)	70/320(23)	9/26(36)	12/66(18.5)	.36
150-400			284(71.9)	221/320(72.5)	15/26(60)	48/66(73.8)	
> 400			20(5.1)	14/320(4.6)	1/26(4)	5/66(7.7)	
Red blood cell count	10 ¹² /L	[4.0-6.0]	4.6(4.1-5)[400]	4.6(4.1-5)[308]	4.6(4.2-5.1)[26]	4.6(4-5.1)[66]	.77
< 4, n (%)			80(20)	59/320(19.2)	5/26(19.2)	16/66(24.2)	.21
4-6			312(78)	245/320(79.5)	20/26(76.9)	47/66(71.2)	
> 6			8(2)	4/320(1.3)	1/26(3.8)	3/66(4.5)	

190 **Table 2:** Continue

	Median (IQR)		All patients n=412	Medical ward n=320 (77.7%)	Transfer to ICU n=26 (6.3%)	ICU n=66 (16.0%)	P-value ^a
	Units	Reference range					
Hemoglobin	g/L	[120-170]	134(120-147) [400]	134(120-146) [308]	141.5(120.2-147) [26]	135.5(118.2-147.8) [66]	.59
< 120, n (%)			98(24.5)	74/320(24)	6/26(23.1)	18/66(27.3)	.85
120-170			298(74.5)	231/320(75)	20/26(76.9)	47/66(71.2)	
> 170			4(1)	3/320(1)	0/26(0)	1/66(1.5)	
Prothrombin time	%	[70-150]	81(68-89) [313]	82(68-90) [239]	82.5(72-87.2) [20]	75(63-86) [54]	.16
Creatinine	μmol/L	[45-104]	81(65-103)[396]	81(63-101)[305]	84.5(73-95.5)[26]	81(71-122)[65]	.16
< 45, n (%)			9(2.3)	5/320(1.6)	1/26(3.8)	3/66(4.6)	.11
45-104			294(74.2)	233/320(76.4)	20/26(76.9)	41/66(63.1)	
> 104			93(23.5)	67/320(22)	5/26(19.2)	21/66(32.3)	
Urea	mmol/L	[2.5-9.2]	6.5(4.6-9.2)[395]	6.3(4.5-9)[304]	6.8(4.8-8.7)[26]	7(4.9-11.5)[65]	.17
< 3, n (%)			19(4.8)	16/320(5.3)	2/26(7.7)	1/66(1.5)	.19
3-6.4			174(44.1)	141/320(46.4)	9/26(34.6)	24/66(36.9)	
> 6.4			202(51.1)	147/320(48.4)	15/26(57.7)	40/66(61.5)	
AST	U/L	[15-37]	45(32-65.5) [323]	39(28-59) [244]	45(39.5-59) [23]	71.5(57.2-82) [56]	<.001
< 15, n (%)			3(0.9)	3/320(1.2)	0/26(0)	0/66(0)	<.001
15-37			123(38.1)	115/320(47.1)	3/26(13)	5/66(8.9)	
> 37			197(61)	126/320(51.6)	20/26(87)	51/66(91.1)	
ALT	U/L	[13-61]	28.5(18-48.8)[334]	26(17-45.5)[255]	30(21.5-42.5)[23]	40(23.8-74)[56]	.001
< 13, n (%)			31(9.3)	28/320(11)	0/26(0)	3/66(5.4)	.005
13-61			249(74.6)	194/320(76.1)	20/26(87)	35/66(62.5)	
> 61			54(16.2)	33/320(12.9)	3/26(13)	18/66(32.1)	

191

192 **Table 2:** Continue

	Median (IQR)		All patients n=412	Medical ward n=320 (77.7%)	Transfer to ICU n=26 (6.3%)	ICU n=66 (16.0%)	P-value ^a
	Units	Reference range					
LDH	U/L	[87-241]	330.5(236.5-419.8)[134]	313(231.5-402)[111]	381(327-453)[9]	473.5(374-496.5)[14]	.001
< 87, n(%)			1(0.7)	0/320(0)	1/26(11.1)	0/66(0)	.004
87-241			34(25.4)	33/320(29.7)	1/26(11.1)	0/66(0)	
> 241			99(73.9)	78/320(70.3)	7/26(77.8)	14/66(100)	
CRP	mg/L	<3	60.7(23.4-122.2)[378]	49.9(18.3-107)[305]	95.7(53.8-145.5)[26]	139.6(96.7-193.3)[47]	<.001
<5, n (%)			21(5.6)	19/320(6.2)	0/26(0)	2/66(4.3)	<.001
[5-50[145(38.4)	134/320(43.9)	5/26(19.2)	6/66(12.8)	
[50-150]			148(39.2)	113/320(37.0)	15/26(57.7)	20/66(42.6)	
> 150			64(16.9)	39/320(12.8)	6/26(23.1)	19/66(40.4)	
Sodium	mmol/L	[136-145]	137(134-139) [396]	137(134-139) [305]	136.5(133.2-137.8) [26]	136(134-138) [65]	.50
Potassium	mmol/L	[3.5-5.1]	4.1(3.8-4.4) [391]	4.1(3.8-4.4) [301]	4(3.6-4.4) [25]	4.1(3.7-4.4) [65]	>.99

193 COVID-19: coronavirus disease 2019; ICU: intensive care unit; IQR: interquartile range; LOS: length of stay; AST: aspartate aminotransferase, ALT: alanine aminotransferase;

194 LDH: lactate dehydrogenase; CRP: C-reactive protein

195 ^aP Values indicate differences between at least two groups of patients out of the three groups: patients admitted to medical wards, patients transferred from medical wards

196 to ICUs and patients admitted to ICUs.

197 *P* < .05 was considered statistically significant

198 ^c[n] indicates the patients without missing values for continuous variable

199 **Patient determinants associated with direct admission/transfer to ICUs**

200 The analysis was based on 374 patients with complete biological data. The crude case fatality
201 rate was not statistically different between included patients and excluded patients (20.0%
202 (75/374) vs 31.6%, (12/38); $P = .15$).

203 Demographic, clinical and biological characteristics on admission associated with direct
204 admission or subsequent transfer to ICUs are summarized in Table 3. Men had a twice higher
205 risk of being hospitalized/transferred to ICUs (OR, 1.99 [95%CI, 1.07-3.73]; $P = .03$).
206 Temperature (OR, 1.37 [95%CI, 1.01-1.88] per degree Celsius increase; $P = .05$) and abnormal
207 lung auscultation on admission (OR, 2.62 [95%CI, 1.40-4.90]; $P = .003$) were associated with
208 a higher risk of admission/transfer to ICUs. The odds of admission/transfer to ICUs revealed
209 a statistically significant increasing trend with an elevated level of CRP (OR, 6.96 [95%CI,
210 1.45-33.35 for CRP > 100mg/L vs CRP < 10mg/L; $P = .02$). Increased time from symptom onset
211 to hospital admission was also significantly associated with ICU hospitalization/transfer to
212 ICUs (OR, 4.82 [95%CI, 1.61-14.43] for a time > 10 days vs a time < 3 days; $P = .0053$).
213 Monocytopenia was associated with increased risk of ICU hospitalization (OR, 2.49 [95%CI,
214 1.29-4.82] $P = .007$) while monocytosis was associated with a lower risk of
215 admission/transfer to ICUs (OR, 0.25 [95%CI, 0.05-1.13]; $P = .005$).

216 **Table 3:** Table 3: Determinants associated with admission to intensive care units in 374
 217 Covid-19 patients at Lyon University hospitals, France

	Adjusted OR	95%CI	P-value
Sex			
Female	1(ref)		
Male	1.99	1.07-3.72	.03
Temperature, C^{aa}			
	1.37	1.01-1.88	.05
Abnormal lung auscultation			
No	1(ref)		
Yes	2.62	1.40-4.90	.003
C Reactive Protein, mg/L^b (Normal range <5 mg/L)			
< 10	1(ref)		
10-100	2.23	0.46-10.85	.32
> 100	6.96	1.45-33.35	.02
Monocyte count, x10⁹/L^b (Normal range 0.2-0.9 x10 ⁹ /L)			
0.3-0.8	1(ref)		
< 0.3	2.49	1.29-4.82	.007
> 0.8	0.25	0.05-1.13	.07
Onset of symptoms and hospital admission, d			
< 3	1(ref)		
3 - 10	2.67	1.02-6.97	.05
> 10	4.82	1.61-14.43	.005

218 OR: odds ratio, CI: confident interval

219 In multivariable logistic regression: i) ICU admission was the dependant variable and ii) sex,
 220 continuous temperature, abnormal lung auscultation, C-reactive protein, monocyte count,
 221 time between the onset of symptoms and hospital admission discretized into 3 categories
 222 were additive independent variables, Akaike information criterion, (AIC) = 307.7, test of
 223 Hosmer and Lemeshow goodness of fit with 20 bins: $P = 0.26$

224 ^aodds ratio of ICU admission was multiplied by 1.37 per degree celsius increase

225 ^bFor laboratory variables, limits of the normal range could have been changed to have at
 226 least 10% (/374) of observations in each category after variable discretization.

227 **Discussion and conclusions**

228 To the best of our knowledge, this report is the largest series of hospitalized COVID-19
229 patients with complete follow-up data in France and complete epidemiological information
230 already available from other European countries [13-15]. Overall, 16.6% of the patients were
231 directly admitted to ICUs and 6.3% were transferred to ICUs from medical wards. The study
232 comprised 412 patients with 87 deaths and 325 patients discharged alive.

233 The observed case fatality rate of 21.1% in this series is higher than those reported in
234 China [16, 17], similar to what has been observed in New York City [18] and lower than the
235 mortality rates of 26% reported in ICU-hospitalized patients in Lombardy [13]. The relatively
236 younger age of patients in the Chinese studies (median ages: 56 and 49 respectively) could
237 explain the lower mortality rates reported in these studies.

238 The most commonly known manifestations of the disease i.e. cough, weakness and
239 fever on admission in our patients were in general similar to those reported in other studies
240 [16, 19, 20]. As reported earlier, cardiovascular diseases and diabetes were the most
241 common comorbidities [17, 21].

242 In agreement with the results of a recent single-arm meta-analysis [22], men accounted
243 for a higher proportion of COVID-19 patients than women in the present study. Similar
244 findings have been reported for MERS-CoV [23]. Women and men traditionally differ in their
245 perceptions of risk [24]. In women, better adoption of protective behavior such as hand-
246 washing [25], in particular in the context of a pandemic [26], could at least in part explain the
247 observed results.

248 Consistent with respiratory viral infections, our hospitalized patients had lymphopenia
249 and elevated levels of LDH and CRP. Lymphopenia and increased levels of LDH and CRP were
250 also reported in the meta-analysis of 1994 COVID-19 patients [20].

251 Few studies have evaluated clinical characteristics on admission that could predict
252 direct hospitalization or subsequent transfer to ICUs. Our results suggest that compared with
253 non-ICU patients, male gender, temperature, abnormal lung auscultation on admission, high
254 levels of CRP, monocytopenia and increased time between onset of symptoms and hospital
255 admission could increase the risk of admission/transfer to ICUs. A high level of CRP has been
256 reported to be an independent risk factor to assess the severity of COVID-19 [27].

257 The time between the onset of symptoms and hospital admission was strongly
258 associated with ICU admission and could be influenced by multiple determinants such as
259 age, socio-economic status, personal risk perception, access to care, geographic factors, and
260 tools used by physicians for remote management of patients. The time between the onset of
261 symptoms and hospital admission was inversely associated with age in our study with a
262 shorter time for older patients ($p < 0.05$) (Supplementary material). This correlation could
263 explain the lack of independent association between age and outcome when age was
264 introduced after the time in the multivariable model. The time to admission could be
265 reduced through public health messages and appropriate guidelines. In addition, we can
266 speculate that this time also provides opportunities for inter-human transmission at the
267 early stages of the disease before hospitalization [19].

268 The prospective design, inclusion of both severe and non-severe cases and complete
269 follow-up of the study population are the main strengths of the present study. Multivariable
270 analysis was based on 374 patients with complete biological data. However, selection bias
271 remains low since the case fatality rate did not differ between patients who were included
272 and not included in the model. Only biological measures on admission were analyzed
273 because repeated measurements were most likely only performed in more severe cases.

274 In conclusion, even if early clinical and pathogenic events of the SARS-CoV-2 infection
275 contribute to the prognosis, the time between the onset of symptoms and hospital
276 admission should be considered as warning markers for more severe pathogenic processes
277 associated with the spectrum of outcomes. This time could be reduced through appropriate
278 preventive measures.

279 **Acknowledgements**

280 The authors express their gratitude to 1) the Department of Health Data of Lyon Hospital: Pr.
281 A. Duclos, Pr. F. Gueyffier, S. Vautier and M. Hervé for the creation and management of e-
282 CRF, 2) Clinical research associates for data collection and data entry: V. Artizzu, L. Bissuel, S.
283 Bennina, L. Dehina-Khenniche, A. Darrin, M. Grange, B. Robin, 3) staff of the virology
284 laboratory of the Lyon hospital: Claire Bandolo, Genevieve Billaud, Maude Bouscambert-
285 Duchamp, Emilie Frobert, Alexandre Gaymard, Laurence Josset, Christophe Ramiere, Isabelle
286 Schuffenecker, Solange Telusson, Martine Valette, Florence Morfin for providing the results
287 of RT-PCR tests.

288 **References**

- 289 [1] Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV
290 epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus
291 outbreak in Wuhan, China. *Int J Infect Dis.* 2020; 91:264-266. doi: 10.1016/j.ijid.2020.01.009.
- 292 [2] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients
293 with Pneumonia in China, 2019. *N Engl J Med.* 2020;382(8):727-733.
294 doi:10.1056/NEJMoa2001017.
- 295 [3] Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan,
296 China: The mystery and the miracle. *J Med Virol.* 2020;92(4):401-402.
297 doi:10.1002/jmv.25678.
- 298 [4] Lupia T, Scabini S, Mornese Pinna S, Di Perri G, De Rosa FG, Corcione S. 2019 novel
299 coronavirus (2019-nCoV) outbreak: A new challenge [published online ahead of print, 2020
300 Mar 7]. *J Glob Antimicrob Resist.* 2020; 21:22-27. doi: 10.1016/j.jgar.2020.02.021.
- 301 [5] Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic
302 infections with COVID-19 screened among close contacts in Nanjing, China. *Sci China Life Sci.*
303 2020;63(5):706-711. doi:10.1007/s11427-020-1661-4.
- 304 [6] Perlman S. Another Decade, Another Coronavirus. *N Engl J Med.* 2020;382(8):760-762.
305 doi:10.1056/NEJMe2001126.
- 306 [7] Bernard Stoecklin S, Rolland P, Silue Y, Mailles A, Campese C, Simondon A, et al. First
307 cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and
308 control measures, January 2020. *Euro Surveill.* 2020;25(6):2000094. doi:10.2807/1560-
309 7917.ES.2020.25.6.2000094.
- 310 [8] Santé Publique France. [20](https://www.santepubliquefrance.fr/maladies-et-
311 traumatismes/maladies-et-infections-respiratoires/infection-a-</p></div><div data-bbox=)

- 312 [coronavirus/articles/infection-au-nouveau-coronavirus-sars-cov-2-covid-19-france-et-](https://doi.org/10.1101/2020.06.09.20125286)
313 [monde#block-242818](#). (Accessed on May 4 2020)
- 314 [9] Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High
315 prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
316 requiring invasive mechanical ventilation [published online ahead of print, 2020 Apr 9].
317 Obesity (Silver Spring). 2020;10.1002/oby.22831. doi:10.1002/oby.22831.
- 318 [10] Saadatian-Elahi M, Picot-Sanchez V, Hénaff L, Pradel F, Escuret V, Dananché C, et al.
319 MedRxiv 2020.04.08.20057471; doi: <https://doi.org/10.1101/2020.04.08.20057471>.
- 320 [11] World Health Organisation. Coronavirus disease 2019 (COVID-19) Situation Report – 70.
321 Page 9. [https://www.who.int/docs/default-source/coronaviruse/situation-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200330-sitrep-70-covid-19.pdf?sfvrsn=7e0fe3f8_2)
322 [reports/20200330-sitrep-70-covid-19.pdf?sfvrsn=7e0fe3f8_2](#).
- 323 [12] Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of
324 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045.
325 doi:10.2807/1560-7917.ES.2020.25.3.2000045.
- 326 [13] Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline
327 Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs
328 of the Lombardy Region, Italy [published online ahead of print, 2020 Apr 6]. JAMA.
329 2020;323(16):1574-1581. doi:10.1001/jama.2020.5394.
- 330 [14] Spiteri G, Fielding J, Diercke M, Campese C, Enouf V, Gaymard A, et al. First cases of
331 coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21
332 February 2020. Euro Surveill. 2020;25(9):2000178. doi:10.2807/1560-
333 7917.ES.2020.25.9.2000178.

- 334 [15] Hodcroft EB. Preliminary case report on the SARS-CoV-2 cluster in the UK, France, and
335 Spain. *Swiss Med Wkly*. 2020;150(9-10):10.4414/smw.2020.20212. Published 2020 Feb 27.
336 doi:10.4414/smw.2020.20212
- 337 [16] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138
338 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China
339 [published online ahead of print, 2020 Feb 7]. *JAMA*. 2020;323(11):1061-1069.
340 doi:10.1001/jama.2020.1585.
- 341 [17] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected
342 with 2019 novel coronavirus in Wuhan, China [published correction appears in *Lancet*. 2020
343 Jan 30]. *Lancet*. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5.
- 344 [18] Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.
345 Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized
346 With COVID-19 in the New York City Area [published online ahead of print, 2020 Apr 22].
347 *JAMA*. 2020; e206775. doi:10.1001/jama.2020.6775.
- 348 [19] Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in
349 Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med*.
350 2020;382(13):1199-1207. doi:10.1056/NEJMoa2001316.
- 351 [20] Borges do Nascimento IJ, Cacic N, Abdulazeem HM, von Groote TC, Jayarajah U,
352 Weerasekera I, et al. Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review
353 and Meta-Analysis. *J Clin Med*. 2020;9(4): E941. Published 2020 Mar 30.
354 doi:10.3390/jcm9040941.
- 355 [21] Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact
356 on 1590 patients with Covid-19 in China: A Nationwide Analysis [published online ahead of
357 print, 2020 Mar 26]. *Eur Respir J*. 2020;2000547. doi:10.1183/13993003.00547-2020.

- 358 [22] Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients' clinical
359 characteristics, discharge rate, and fatality rate of meta-analysis [published online ahead of
360 print, 2020 Mar 12]. *J Med Virol*. 2020;10.1002/jmv.25757. doi:10.1002/jmv.25757.
- 361 [23] Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory
362 syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. *Int J Infect Dis*.
363 2016; 49:129-133. doi: 10.1016/j.ijid.2016.06.015.
- 364 [24] Gustafson PE. Gender differences in risk perception: theoretical and methodological
365 perspectives. *Risk Anal*. 1998;18(6):805–811. doi:10.1023/b:rian.0000005926.03250.c0.
- 366 [25] Srivastav A, Santibanez TA, Lu PJ, Stringer MC, Dever JA, Bostwick M, et al. Preventive
367 behaviors adults report using to avoid catching or spreading influenza, United States, 2015-
368 16 influenza season. *PLoS One*. 2018;13(3): e0195085. Published 2018 Mar 30. doi:
369 10.1371/journal.pone.0195085.
- 370 [26] Fung IC, Cairncross S. How often do you wash your hands? A review of studies of hand-
371 washing practices in the community during and after the SARS outbreak in 2003. *Int J*
372 *Environ Health Res*. 2007;17(3):161-183. doi:10.1080/09603120701254276.
- 373 [27] Zhu Z, Cai T, Fan L, Lou K, Hua X, Huang Z, et al. Clinical value of immune-inflammatory
374 parameters to assess the severity of coronavirus disease 2019 [published online ahead of
375 print, 2020 Apr 22]. *Int J Infect Dis*. 2020; S1201-9712(20)30257-5. doi:
376 10.1016/j.ijid.2020.04.041.

377 **Supporting information**

378 Distribution of the time between the onset of symptoms and hospital admission by age

379 category